This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: "PSivida" – news · newspapers · books · scholar · JSTOR (March 2020) (Learn how and when to remove this message)


pSivida Corp.
Company typePublic company
Nasdaq: PSDV ASX: PVA FWB: PV3
IndustryPharmaceuticals
Headquarters
Watertown, Massachusetts
,
USA
Number of locations
2
ProductsIluvien
Websitewww.psivida.com

EyePoint Pharmaceuticals, Inc. (formerly pSivida Corp.) pSivida is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.

pSivida obtained porous silicon technology from the British government Defence Evaluation and Research Agency (DERA, now QinetiQ).[citation needed] QinetiQ continues to be a strategic partner.[1][2]

In June 2004, pSivida acquired full ownership of pSiMedica.[1] In April 2018, pSivida purchased eye products firm Icon Bioscience.[3][4]

See also

References

  1. ^ a b "PSivida lifts pSiMedica stake to 100%". The Sydney Morning Herald. 2004-06-02. Retrieved 2020-10-29.
  2. ^ "Nano silicon boosts tumour fight". 2004-06-18. Retrieved 2020-10-29.
  3. ^ "BRIEF—pSivida to buy eye products firm Icon Bioscience". The Pharma Letter. Retrieved 2018-06-22.
  4. ^ "BRIEF-pSivida Corp Announces Transformative Acquisition Of Icon Bioscience". Reuters. 2018-03-28. Retrieved 2020-10-29.

External links


QinetiQ
Authority control databases
Categories